Table 1.

Baseline characteristics and number of events in exposure groups

	Bezafibrate	All other fibrates	P value for difference
n	12,161	4,191
Person-years	32,091	9,067
Mean duration of use (years)	2.6	2.2	<0.0001
Mode year of treatment initiation	1993	1994	<0.0001
Age (years)
50	20	22	0.0112
50–59	33	33	0.9840
60–69	37	33	<0.0001
>69	10	12	0.0008
Male sex	52	60	<0.0001
History of myocardial infarction	1	1	0.7529
History of stroke	0	0	0.9676
History of ACE inhibitor/angiotensin receptor blocker use	5	6	0.0018
History of calcium channel blocker use	24	22	0.1756
History of β-blocker use	16	17	0.2382
History of loop diuretic use	5	5	0.2178
History of thiazide diuretic use	9	8	0.2883
History of corticosteroid use	3	3	0.6388
Never smoker	19	21	0.5114
Ever smoker	39	41	0.5114
Not reported	42	38	<0.0001
BMI
<25 kg/m2	9	8	0.0449
25–29.9 kg/m2	13	13	0.6363
>29.9 kg/m2	5	6	0.0035
Not reported	73	72	0.0523
Number of cases of incident diabetes	272	131
Cases/1,000 person-years (95% CI)	8.5 (7.5–9.5)	14.4 (12.1–17.1)	<0.001

Data are % unless indicated otherwise. Individuals with baseline diabetes were excluded. History of cardiovascular events and drug use refer to history in the year before cohort entry. P values were generated using χ² and t tests.